AI Verdict
PBSV has stronger fundamentals based on our AI analysis.
PCSA vs PBSV Fundamental Comparison
| Metric | PCSA | PBSV |
|---|---|---|
| Revenue | $0.0 | $2.3M |
| Net Income | $-13.6M | $32,860.0 |
| Net Margin | N/A | 1.4% |
| ROE | -243.2% | 0.3% |
| ROA | -173.6% | 0.2% |
| Current Ratio | 2.54x | 4.03x |
| Debt/Equity | 0.00x | 0.00x |
| EPS | $-10.36 | $0.00 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
PCSA vs PBSV: Frequently Asked Questions
Is PCSA or PBSV a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), PBSV has stronger fundamentals. PCSA is rated STRONG SELL (87% confidence) while PBSV is rated SELL (78% confidence). This is not investment advice.
How does PCSA compare to PBSV fundamentally?
Processa Pharmaceuticals, Inc. has ROE of -243.2% vs Pharma-Bio Serv, Inc.'s 0.3%. Net margins are N/A vs 1.4% respectively.
Which stock pays higher dividends, PCSA or PBSV?
PCSA has a dividend yield of N/A or no dividend while PBSV has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in PCSA or PBSV for long term?
For long-term investing, consider that PCSA has STRONG SELL rating with 87% confidence, while PBSV has SELL rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about PCSA vs PBSV?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For PCSA vs PBSV, the AI consensus favors PBSV based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.